13.11
1.39%
0.18
After Hours:
13.15
0.04
+0.31%
Third Harmonic Bio Inc stock is traded at $13.11, with a volume of 1.34M.
It is up +1.39% in the last 24 hours and down -0.30% over the past month.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
See More
Previous Close:
$12.93
Open:
$13.07
24h Volume:
1.34M
Relative Volume:
5.89
Market Cap:
$583.73M
Revenue:
-
Net Income/Loss:
$-32.74M
P/E Ratio:
-8.3408
EPS:
-1.5718
Net Cash Flow:
$-24.89M
1W Performance:
+12.82%
1M Performance:
-0.30%
6M Performance:
-6.29%
1Y Performance:
+69.60%
Third Harmonic Bio Inc Stock (THRD) Company Profile
Name
Third Harmonic Bio Inc
Sector
Industry
Phone
(209) 727-2457
Address
1700 MONTGOMERY STREET, SAN FRANCISCO
Compare THRD with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
THRD
Third Harmonic Bio Inc
|
13.11 | 583.73M | 0 | -32.74M | -24.89M | -1.5718 |
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-09-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jun-18-24 | Initiated | Stifel | Buy |
Jun-07-24 | Initiated | Raymond James | Outperform |
Dec-16-22 | Downgrade | Jefferies | Buy → Hold |
Dec-15-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Oct-10-22 | Initiated | Cowen | Outperform |
Oct-10-22 | Initiated | Jefferies | Buy |
Oct-10-22 | Initiated | Morgan Stanley | Overweight |
View All
Third Harmonic Bio Inc Stock (THRD) Latest News
How the (THRD) price action is used to our Advantage - Stock Traders Daily
Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference - Marketscreener.com
Third Harmonic Bio to Present at Evercore HealthCONx Conference in December | THRD Stock News - StockTitan
Wall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to Trade - MSN
(THRD) Technical Pivots with Risk Controls - Stock Traders Daily
RA Capital Management Reduces Stake in Third Harmonic Bio Inc - GuruFocus.com
Significant Stake Increase by T. Rowe Price in Third Harmonic Bi - GuruFocus.com
Vertiv Rises 13% in a Month: Time for Investors to Buy the Stock? - MSN
Shiba Inu (SHIB) Price Rises 53% but Hits Rejection at Key Ascending Resistance Level - MSN
Third Harmonic Bio Reports Q3 2024 Financial Results - TipRanks
Third Harmonic Bio Inc (THRD) Quarterly 10-Q Report - Quartzy
Third Harmonic Bio (THRD) to Present at Major Stifel, Jefferies Healthcare Conferences | THRD Stock News - StockTitan
Marquis Who's Who Honors Jonathan Colon, PhD, for Expertise in Biotechnology - 24-7 Press Release
Third Harmonic Flat on Q3 Results - Baystreet.ca
Third Harmonic Bio Announces Third Quarter 2024 Financial Results - The Manila Times
Third Harmonic Bio Reports $296M Cash Position, Phase 1 Trial Progress Despite Wider Q3 Loss | THRD Stock News - StockTitan
An RNAi renaissance is creating a new generation of startups - BioPharma Dive
(THRD) Technical Data - Stock Traders Daily
Third harmonic bio sees $14.3 million in stock sales by BVF Partners - Investing.com India
Jade, another biotech spinout of Paragon, to merge with Aerovate - BioPharma Dive
Third Harmonic Bio's chief medical officer sells $40,095 in stock - Investing.com
A new biotech, built around protein design, springs from David Baker’s lab - BioPharma Dive
Down -18.64% in 4 Weeks, Here's Why Philips (PHG) Looks Ripe for a Turnaround - MSN
Harmonic Announces Third Quarter 2024 Results - Yahoo Finance
Where are the Opportunities in (THRD) - Stock Traders Daily
Harmonic Discovery presents FLT3 kinase inhibitor with enhanced safety profile - BioWorld Online
Revvity Earnings Preview: What to Expect - MSN
Forbion follows string of startup exits with $2.2B fundraise - BioPharma Dive
(THRD) Trading Signals - Stock Traders Daily
Upstream prices $255M IPO in bid to challenge Amgen, AstraZeneca asthma drug - BioPharma Dive
Startup led by John Maraganore raises $135M to build ‘future of RNAi’ - BioPharma Dive
Third Harmonic Bio: Nothing Stands Out (NASDAQ:THRD) - Seeking Alpha
Judo Bio debuts with $100M and a plan to take RNA drugs to the kidney - BioPharma Dive
How To Trade (THRD) - Stock Traders Daily
Third Harmonic Bio's SWOT analysis: oral KIT inhibitor stock shows promise By Investing.com - Investing.com South Africa
Third Harmonic Bio's SWOT analysis: oral KIT inhibitor stock shows promise - Investing.com
WAVE Life Sciences (NASDAQ:WVE) Stock Quotes, Forecast and News Summary - Benzinga
Long Term Trading Analysis for (THRD) - Stock Traders Daily
Third Harmonic Bio executive sells shares worth over $71,000 - Investing.com India
Third harmonic bio executive sells over $140k in stock By Investing.com - Investing.com South Africa
Third Harmonic Bio executive sells shares worth over $71,000 By Investing.com - Investing.com Australia
Third harmonic bio executive sells over $140k in stock - Investing.com
Victory Capital Management Inc. Has $1.14 Million Position in Hamilton Lane Incorporated (NASDAQ:HLNE) - Defense World
Highbridge Capital Management LLC Purchases Shares of 630,114 HashiCorp, Inc. (NASDAQ:HCP) - MarketBeat
How the (HRMY) price action is used to our Advantage - Stock Traders Daily
Hyliion Holdings Corporation [HYLN] Records 50-Day SMA of $2.01 - Knox Daily
23andMe faces Nasdaq delisting - MSN
Independent directors resign from 23andMe board after opposing move to privatize - Washington Times
23andMe Stock Falls as All Board Members Resign - Barron's
Finnish Authorities Are After Hex And PulseChain Founder, Richard Heart On Suspicion Of Tax Evasion And Assault - 99Bitcoins
Third Harmonic Bio Inc (THRD) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Third Harmonic Bio Inc Stock (THRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Third Harmonic Bio Inc Stock (THRD) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Conner Edward R. | Chief Medical Officer |
Nov 08 '24 |
Sale |
15.00 |
2,117 |
31,755 |
0 |
BVF PARTNERS L P/IL | See Explanation of Responses |
Oct 29 '24 |
Sale |
14.30 |
1,000,000 |
14,300,000 |
176,692 |
Conner Edward R. | Chief Medical Officer |
Oct 28 '24 |
Option Exercise |
4.20 |
2,673 |
11,227 |
2,673 |
Conner Edward R. | Chief Medical Officer |
Oct 28 '24 |
Sale |
15.00 |
2,673 |
40,095 |
0 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):